Dermatitis, Atopic

The disease is described as genetically determined, indicating a hereditary basis. The supplied literature also supports a multifactorial origin involving genetic disorders, epidermal barrier defects, altered immune responses, and disruption of the skin microbial balance. No single cause is established in the grounding.

Atopic dermatitis has a complex pathophysiology involving barrier dysfunction, immune dysregulation, and microbial imbalance. The literature highlights elevated IL-4 and IL-13 signatures, with these cytokines inhibiting barrier-related proteins such as filaggrin, loricrin, and involucrin through STAT6 and STAT3 signaling. Innate and adaptive immune changes, signal transduction pathways, and gut-skin axis effects involving microbiota-derived metabolites are also implicated.

A hereditary disposition is a risk factor, along with the tendency to form IgE and the associated susceptibility to allergic rhinitis and asthma. The grounding also supports genetic abnormalities, impaired epidermal barrier function, altered immune responses, and skin microbiome disruption as factors associated with disease development or expression. No additional specific demographic or environmental risk factors are supported here.

The supplied reviews indicate that treatment is centered on drug therapy and emerging targeted therapy for a complex inflammatory disease. Approved or highlighted modalities in the grounding include IL-4Rα inhibition, anti-IL-13 therapy, and JAK inhibition, with broader development of additional targeted agents. The literature also mentions microbiome-directed strategies such as probiotics and prebiotics as investigational or adjunctive approaches.